CN111777632A - Preparation method of moxifloxacin hydrochloride chelate - Google Patents
Preparation method of moxifloxacin hydrochloride chelate Download PDFInfo
- Publication number
- CN111777632A CN111777632A CN202010696257.0A CN202010696257A CN111777632A CN 111777632 A CN111777632 A CN 111777632A CN 202010696257 A CN202010696257 A CN 202010696257A CN 111777632 A CN111777632 A CN 111777632A
- Authority
- CN
- China
- Prior art keywords
- reaction
- finished
- acetic acid
- chelate
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 title claims abstract description 26
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 title claims abstract description 25
- 239000013522 chelant Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 78
- 238000006243 chemical reaction Methods 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000002904 solvent Substances 0.000 claims abstract description 21
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000010438 heat treatment Methods 0.000 claims abstract description 13
- 238000001816 cooling Methods 0.000 claims abstract description 9
- -1 cyclic ester Chemical class 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 21
- 238000004321 preservation Methods 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000007363 ring formation reaction Methods 0.000 claims description 6
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 4
- 229960003923 gatifloxacin Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- DFCAFRGABIXSDS-UHFFFAOYSA-N Cycloate Chemical class CCSC(=O)N(CC)C1CCCCC1 DFCAFRGABIXSDS-UHFFFAOYSA-N 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 39
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 229960003702 moxifloxacin Drugs 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000009776 industrial production Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- 206010023644 Lacrimation increased Diseases 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000004317 lacrimation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 239000002351 wastewater Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- GQYBNVXJQVIRGC-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 GQYBNVXJQVIRGC-UHFFFAOYSA-N 0.000 description 1
- YPGNSOQXVZILMR-UHFFFAOYSA-N B(O)(O)O.C(C)(=O)OC(C)=O Chemical compound B(O)(O)O.C(C)(=O)OC(C)=O YPGNSOQXVZILMR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001522633 Betula utilis subsp. albosinensis Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000008830 Carthamus tinctorius Honghua extract Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Abstract
The application provides a preparation method of moxifloxacin hydrochloride chelate, belonging to the technical field of heterocyclic compound preparation. Keeping the acetic acid excessive, adding trimethyl borate into the acetic acid, and reacting at 110-120 ℃; after the reaction is finished, cooling, adding substituted cyclic ester, heating to 110-120 ℃ after the addition is finished, and continuing the reaction; and recovering the fraction under reduced pressure until the reaction is finished, and recovering the solvent until the solvent is dried to obtain the chelate. Has the advantages of simple process, economy, environmental protection, high product purity and the like.
Description
Technical Field
The application relates to a preparation method of moxifloxacin hydrochloride chelate, belonging to the technical field of heterocyclic compound preparation.
Background
Moxifloxacin hydrochloride (chemical name: 1-cyclopropyl-7- { (S, S) -2, 8-diazabicyclo [4.3.0] nonan-8-yl } -6-fluoro-8-methoxy-1, 4-dihydro-4-oxo-3-quinoline carboxylic acid hydrochloride) has the structural formula:
the moxifloxacin hydrochloride is an ultra-broad-spectrum fluoroquinolone medicine, and the antibacterial spectrum of the moxifloxacin hydrochloride covers all main pathogenic bacteria of respiratory tracts. It has low drug resistance, long half-life, strong tissue penetration and high concentration in lung tissue. Liver and kidney discharge. Has excellent pharmacokinetic characteristics. Has good safety and tolerance, and has low toxicity to central nervous system or liver. The dosage of the composition is not required to be adjusted for the elderly, renal dysfunction, and mild hepatic insufficiency. The moxifloxacin has unique curative effects on acute attack of chronic bronchitis and bacterial infection of chronic obstructive pulmonary disease, and has better antibacterial effect on some drug-resistant bacteria.
Moxifloxacin hydrochloride was marketed by bayer corporation on FDA in the united states 12 months 1999, moxifloxacin hydrochloride tablets were approved by SFDA for import and marketed in china 2002, and are currently marketed in over 90 countries and regions including the united states, germany and other european union countries with trade names:
moxifloxacin hydrochloride sodium chloride injection was marketed in the united states in 2001 and in china in 2004 at a dose of 400mg (moxifloxacin)/250 mL, and so far in over 40 countries and regions including the united states, germany and other european union countries.
Currently, moxifloxacin hydrochloride is imitated and produced by a plurality of pharmaceutical enterprises, and the main synthetic routes comprise:
firstly, taking corresponding quinoline carboxylic acid or quinoline ester as a raw material, condensing piperazine with a moxifloxacin side chain, and then salifying (or salifying after hydrolysis) with hydrochloric acid to directly prepare moxifloxacin;
chelating quinoline carboxylic acid or quinoline ester with boron ligand to enhance the activity of quinoline ring, substituting with moxifloxacin side chain, hydrolyzing, and salifying with hydrochloric acid;
③ substituting 8-fluorine substituted quinoline carboxylic acid with moxifloxacin side chain for substituting for methoxyl group by 8-halogen (the route disclosed by original grinding Bayer);
and fourthly, quinoline carboxylic acid and the protected moxifloxacin side chain are subjected to substitution reaction, and then are hydrolyzed and salified to prepare the compound.
Boron trioxide is used as a starting material by Zhejiang Xindong pharmaceutical industry GmbH, and is mixed with trifluoroacetic anhydride to react for 5-10h at 35-40 ℃, and then reacted with quinoline carboxylic acid cyclization ester for 2-3h at 80-100 ℃, cooled to room temperature, added with water, filtered, and washed to be neutral to obtain a product (Honghua bin, CN201110280847.6, 09 months and 21 days 2011).
The method has long reaction time, and simultaneously, due to the use of trifluoroacetic anhydride (an acidic corrosive substance), the method has strong irritation, the generated waste liquid is not easy to treat, and the method has great influence on the environment.
Shenzhen Xin Li Tai pharmaceutical industry, Inc. takes boron trioxide as a starting material, dissolves the boron trioxide in a certain amount of acetic anhydride and acetic acid mixed solution, reacts at 90-120 ℃, and then cools the reaction solution; adding quinoline carboxylic acid cyclic ester into the reaction solution, reacting at the reaction temperature of 50-80 ℃, cooling, adding a certain amount of ether solvent, stirring, filtering, washing with the ether solvent, and drying to obtain the product (Zhang Chang, CN201110170568.4, 15/06/2011).
Mixing boric acid and acetic anhydride for reaction, adding gatifloxacin cyclization ester, cooling to room temperature, adding water, vacuum filtering, and washing to neutrality to obtain the final product (Liucong, Jiangdui, etc., fine chemical intermediate, 33-36 of No. 1 of 2013, page 62).
The patent refers to the field of 'pharmaceutical preparations'.
The acetic anhydride is used in the methods, is easy to prepare drugs, is controlled, has corrosiveness and lacrimation, and needs a large amount of water quenching reaction after the reaction is finished, so that a large amount of waste water and waste acetic acid are generated, cannot be used indiscriminately and do not accord with atom economy; the solid and acetic anhydride are used for chelation in the Fuitai pharmaceutical industry and the Guobao pharmaceutical industry, and sudden energy release and potential safety hazard exist in the chelation process; although the Chengdu Climeng pharmaceutical science and technology company uses liquid triethyl borate to avoid sudden problems, the company also uses anhydrous zinc chloride, which has corrosivity and toxicity, and meanwhile, the method also has the problem of metal residue, which can be complexed with moxifloxacin products to influence the curative effect, and is not beneficial to industrial production.
Disclosure of Invention
In view of the above, the application provides a preparation method of a chelating intermediate suitable for synthesizing moxifloxacin hydrochloride, which has the advantages of simple process, economy, environmental protection and high product purity.
Specifically, the method is realized through the following scheme:
a preparation method of moxifloxacin hydrochloride chelate comprises the steps of mixing trimethyl borate (II) with acetic acid (III), heating to 110-class temperature of 120 ℃, refluxing and stirring for reaction for 1h, cooling to 70 ℃ after the reaction is finished, adding substituted cyclization ester (V), heating to 110-class temperature of 120 ℃ after the addition is finished, continuing stirring for 1.5h, keeping the temperature, recovering a part of fraction under reduced pressure, continuing stirring for 1h, and recovering a solvent to dryness after the reaction is finished to obtain the chelate (I).
The above process can be represented by the following reaction formula:
the preparation method for synthesizing the moxifloxacin hydrochloride chelate intermediate by trimethyl borate comprises the steps of taking trimethyl borate and gatifloxacin hydrochloride as initial raw materials, reacting in acetic acid to synthesize the moxifloxacin hydrochloride chelate, recovering a solvent after the reaction is finished, drying to obtain a product, and obtaining the product, wherein the total molar yield is about 98%. The purity of the product is more than 99.5 percent by HPLC detection. Compared with the conventional moxifloxacin chelate synthesized by boric acid and acetic anhydride through a chelation reaction, the method avoids the use of easily prepared toxic acetic anhydride, avoids the sudden phenomenon of violent energy release during chelation, improves the safety coefficient in the actual production process, realizes the recovery and reuse of the solvent acetic acid, has the characteristics of short steps, simplicity and safety in operation, economy, environmental protection and excellent product quality, and is suitable for industrial production.
Further, as preferable:
the substituted cyclic ester: the molar ratio of trimethyl borate to acetic acid is 1:1:3 to 1:3:9, preferably 1:2: 8.
The reaction temperature was 115 ℃ or 120 ℃.
The method for preparing the chelate intermediate uses trimethyl borate and acetic acid to replace boric acid and acetic anhydride, thereby avoiding potential safety hazard caused by violent energy release due to sudden burst of a solid-liquid reaction system, and the trimethyl borate is liquid, thereby facilitating the metering operation and automatic control in industrial production; the control in purchasing and using caused by using the easily prepared drug acetic anhydride is avoided, and the acetic anhydride is genotoxic impurity, and the residue has influence on the quality of the drug; the method avoids a large amount of waste water and waste acetic acid which are generated by using acetic anhydride boric acid, can not be used indiscriminately and do not accord with atom economy, and the acetic anhydride has strong irritation and lacrimation, and has great occupational hazard to staff in industrial production. The purity of the chelating intermediate prepared by the method is more than 99.5%, the operation is simple and convenient, and the method is economic and environment-friendly.
Detailed Description
Example 1
Mixing 10.39g (2eq) trimethyl borate with 24g (8eq) acetic acid, heating to 110-120 ℃, refluxing and stirring for reaction for 1h, cooling to 70 ℃ after the reaction is finished, adding 16.16g substituted cyclic ester, heating to 115 ℃, keeping the temperature and stirring for reaction for 1.5 h. After the heat preservation, 10g of fraction is recovered under reduced pressure, and the heat preservation and the stirring are continued for 1 hour. After the reaction, the solvent was recovered under reduced pressure to dryness to obtain 21.2g of crude product with a mass yield of 131.19% (calculation formula: powder yield/charge of the main material (gatifloxacin) 100%) and an HPLC analysis content of 99.59%.
Example 2
Mixing 31.17g (2eq) trimethyl borate with 72g (8eq) acetic acid, heating to 110-120 ℃, refluxing and stirring for reaction for 1h, cooling to 70 ℃ after the reaction is finished, adding 48.48g substituted cyclic ester, heating to 115 ℃, keeping the temperature and stirring for reaction for 1.5 h. After the heat preservation, 32g of fraction is recovered under reduced pressure, and the heat preservation and the stirring are continued for 1 hour. After the reaction, the solvent was recovered to dryness to obtain 64.2g of crude product with a mass yield of 132.43% (calculation formula: 64.2/48.48 × 100% ═ 132.43%), and an HPLC analysis content of 99.70%.
Example 3
62.35g (2eq) trimethyl borate is mixed with 144g (8eq) acetic acid, the temperature is raised to 110-120 ℃, reflux and stirring are carried out for reaction for 1 hour, after the reaction is finished, the temperature is lowered to 70 ℃, 96.96g substituted cyclized ester is added, the temperature is raised to 120 ℃, and the temperature is kept and the stirring is carried out for reaction for 1.5 hours. After the heat preservation, 64g of fraction is recovered under reduced pressure, and the heat preservation and the stirring are continued for 1 hour. After the reaction, the solvent was recovered to dryness to give 128.3g of crude product in 132.32% mass yield (calculation formula: 128.3/96.96 × 100%: 132.32%), and 99.62% content by HPLC analysis.
Comparative example: CN 104031043A
The example 2 with the highest yield in the invention patent application with application number 2014102322334 (publication number CN 104031043a) was selected as a comparison case, and compared with the technical scheme in the present application.
Compared with the comparative example, the advantages of the scheme are mainly shown in the following aspects:
(1) in the aspect of cost: the reaction requires less solvent types in the present case than in the comparative case; the auxiliary agent anhydrous zinc chloride is not needed; the reaction time is shorter; the post-treatment mode is simple, and ethanol is not needed for multiple rinsing; acetic anhydride is cut and discarded, so that a large amount of waste water is avoided; only the solvent acetic acid is used, and the solvent acetic acid can be repeatedly used; the yield is higher, the unit consumption is lower, and the cost is more advantageous;
(2) and (3) safety aspect: acetic anhydride has strong irritation and lacrimation, and has great occupational hazard to operators in industrial production, the safety risk is avoided by using acetic acid, trimethyl borate (liquid) is used for replacing boric acid (solid), fluid conveying can be used, the sealing performance is better, automatic control is more convenient to realize, and the safety coefficient is higher; the anhydrous zinc chloride has corrosivity and toxicity, and has the problem of metal residue after use, and the anhydrous zinc chloride can be complexed with moxifloxacin products to influence the curative effect;
(3) and (3) quality aspect of finished products: compared with the comparative case, the quality yield of the case is improved by about 36 percent (the quality yield of the case is about 132 percent, and the quality yield of the comparative case is about 95.33 percent), the content of the liquid phase detected by the case in the aspect of purity is more than 99.5 percent, and the purity of the comparative case fluctuates between 99.2 percent and 99.55 percent.
(4) Impurity aspect: compared with the comparative case, the purity of the comparative case is poorer, the stability is not good, the quality of the comparative case is stable, the purity is higher, and no additional impurity is generated. The acetic anhydride left in the reaction can react with the subsequent moxifloxacin small ring to acylate the moxifloxacin small ring to form acylated impurities, so that the impurity risk is increased.
(5) And (3) post-treatment: the method is the same as the comparative case, and after post-treatment, the subsequent reaction can be directly carried out by using solvent dissolution without separately taking out or drying the solid, and the operation is fluidized; the dissolved moxifloxacin hydrochloride can also directly participate in the subsequent reaction, and the moxifloxacin hydrochloride at the later stage is easy to process and convenient to operate, and does not need additional post-treatment.
Claims (8)
1. A preparation method of moxifloxacin hydrochloride chelate is characterized by comprising the following steps: keeping the acetic acid excessive, adding trimethyl borate into the acetic acid, and reacting at 110-120 ℃; after the reaction is finished, cooling, adding substituted cyclic ester, heating to 110-120 ℃ after the addition is finished, and continuing the reaction; recovering the fraction under reduced pressure until the reaction is finished, recovering the solvent to be dry to obtain the product with the structure
The chelate of (2).
2. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, characterized in that: mixing trimethyl borate with acetic acid, heating to 110-120 ℃, refluxing and stirring for reaction, cooling to 70 ℃ after the reaction is finished, adding substituted cyclized ester, heating to 110-120 ℃, continuing stirring, keeping the temperature, recovering partial fraction under reduced pressure, continuing stirring until the reaction is finished, and recovering the solvent until the solvent is dried to obtain the chelate.
3. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, wherein the ratio of gatifloxacin cyclization ester: the molar ratio of trimethyl borate to acetic acid is 1:1:3-1:3: 9.
4. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, wherein the ratio of gatifloxacin cyclization ester: the molar ratio of trimethyl borate to acetic acid was 1:2: 8.
5. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, characterized in that: the reaction temperature of trimethyl borate and acetic acid is 115 ℃ or 120 ℃, and the reaction temperature of the reaction product of trimethyl borate and acetic acid and the addition cyclization ester is 115 ℃ or 120 ℃.
6. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, characterized in that: mixing 10.39g trimethyl borate with 24g acetic acid, heating to 110-; after the heat preservation is finished, 10g of fraction is recovered under reduced pressure, and the heat preservation and the stirring are continued for 1 hour; after the reaction is finished, the solvent is recovered under reduced pressure until the solvent is dried, and a crude product is obtained.
7. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, characterized in that: mixing 31.17g trimethyl borate with 72g acetic acid, heating to 110-120 ℃, refluxing, stirring and reacting for 1h, cooling to 70 ℃ after the reaction is finished, adding 48.48g substituted cycloate, heating to 115 ℃, keeping the temperature, stirring and reacting for 1.5 h; after the heat preservation is finished, 32g of fractions are recovered under reduced pressure, and the heat preservation and the stirring are continued for 1 hour; and recovering the solvent to be dry after the reaction is finished to obtain a crude product.
8. The method for preparing moxifloxacin hydrochloride chelate according to claim 1, characterized in that: 62.35g of trimethyl borate is mixed with 144g of acetic acid, the mixture is heated to 110-120 ℃ and then is refluxed and stirred for reaction for 1 hour, after the reaction is finished, the temperature is reduced to 70 ℃, 96.96g of substituted cycloate is added, the temperature is raised to 120 ℃, and the mixture is kept warm and stirred for reaction for 1.5 hours; after the heat preservation is finished, 64g of fraction is recovered under reduced pressure, and the heat preservation and the stirring are continued for 1 hour; and recovering the solvent to be dry after the reaction is finished to obtain a crude product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010696257.0A CN111777632A (en) | 2020-07-20 | 2020-07-20 | Preparation method of moxifloxacin hydrochloride chelate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010696257.0A CN111777632A (en) | 2020-07-20 | 2020-07-20 | Preparation method of moxifloxacin hydrochloride chelate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111777632A true CN111777632A (en) | 2020-10-16 |
Family
ID=72764227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010696257.0A Pending CN111777632A (en) | 2020-07-20 | 2020-07-20 | Preparation method of moxifloxacin hydrochloride chelate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111777632A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1059527A (en) * | 1990-07-06 | 1992-03-18 | 杏林制药株式会社 | (6,7-substituted-8-alkoxy base-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinoline carboxylic acid-O 3,-O 4) two (boric acid ester of acyloxy-O) and salt thereof and their preparation methods |
| CN1616456A (en) * | 2004-09-28 | 2005-05-18 | 南京圣和药业有限公司 | Preparation of catifloxacin and purifying method |
| CN1660838A (en) * | 2004-12-30 | 2005-08-31 | 南京圣和药业有限公司 | Method for preparing and purifying laevogyrate gatifloxacin |
| CN102558145A (en) * | 2011-12-14 | 2012-07-11 | 中国药科大学 | Method for preparing balofloxacin |
| CN104031043A (en) * | 2014-05-28 | 2014-09-10 | 成都克莱蒙医药科技有限公司 | Novel synthesis method of moxifloxacin hydrochloride |
| CN104230924A (en) * | 2013-08-15 | 2014-12-24 | 江苏天一时制药有限公司 | Synthetic method of moxifloxacin hydrochloride |
| CN104860944A (en) * | 2015-06-09 | 2015-08-26 | 内蒙古东北六药集团有限公司 | Production method of moxifloxacin hydrochloride |
-
2020
- 2020-07-20 CN CN202010696257.0A patent/CN111777632A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1059527A (en) * | 1990-07-06 | 1992-03-18 | 杏林制药株式会社 | (6,7-substituted-8-alkoxy base-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinoline carboxylic acid-O 3,-O 4) two (boric acid ester of acyloxy-O) and salt thereof and their preparation methods |
| CN1616456A (en) * | 2004-09-28 | 2005-05-18 | 南京圣和药业有限公司 | Preparation of catifloxacin and purifying method |
| CN1660838A (en) * | 2004-12-30 | 2005-08-31 | 南京圣和药业有限公司 | Method for preparing and purifying laevogyrate gatifloxacin |
| CN102558145A (en) * | 2011-12-14 | 2012-07-11 | 中国药科大学 | Method for preparing balofloxacin |
| CN104230924A (en) * | 2013-08-15 | 2014-12-24 | 江苏天一时制药有限公司 | Synthetic method of moxifloxacin hydrochloride |
| CN104031043A (en) * | 2014-05-28 | 2014-09-10 | 成都克莱蒙医药科技有限公司 | Novel synthesis method of moxifloxacin hydrochloride |
| CN104860944A (en) * | 2015-06-09 | 2015-08-26 | 内蒙古东北六药集团有限公司 | Production method of moxifloxacin hydrochloride |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101838238B (en) | Method for synthesizing quinolone main cycle compound | |
| CN101778821A (en) | Synthesizing of N-(4-luorobenzyl)-N-(1-methyl piperidine-4-yl)-N '-(4-(2-methyl propoxy-) phenyl methyl) urea and tartrate and crystal formation | |
| EP2089388A2 (en) | Process for the synthesis of moxifloxacin hydrochloride | |
| CN101298452A (en) | Preparing methods and uses of S-(-)-nadifloxacin and water soluble salt thereof | |
| EP0190915B1 (en) | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | |
| CN110194767A (en) | A kind of preparation method of moxifloxacin hydrochloride and its intermediate | |
| SK14672001A3 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
| CN111777632A (en) | Preparation method of moxifloxacin hydrochloride chelate | |
| CN110467600A (en) | A kind of De Lasha star meglumine salt crystal form L and preparation method thereof | |
| US6576764B2 (en) | Synthesis and crystallization of piperazine ring-containing compounds | |
| JPS63295561A (en) | 2-quinolone derivative | |
| CN109293631B (en) | Preparation method of 3-amino-N- (2, 6-dioxo-3-piperidyl) -phthalimide compound | |
| CN112358490A (en) | Preparation method of tetramisole hydrochloride | |
| CN101981004B (en) | Novel crystalline forms | |
| CN104628728A (en) | Pralatrexate preparation method | |
| CN112759590B (en) | Preparation method of moxifloxacin | |
| CN108658931A (en) | A kind of preparation method of Raltitrexed key intermediate | |
| CN1012501B (en) | Quinolonecarboxylic acid derivatives and their preparation | |
| JPS62135458A (en) | Novel quinolone compound and production thereof | |
| CN113214321B (en) | Preparation method of minodronate E crystal form | |
| CA1189509A (en) | Substituted 11-oxo-11h-pyrido [2,1-b] quinazolines | |
| CN114539244B (en) | Preparation method of moxifloxacin hydrochloride | |
| EP0216323A2 (en) | Quinolonecarboxylic acid derivatives and their preparation | |
| AU781221B2 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
| CN105130987B (en) | A kind of synthetic method of medicine intermediate pyrrolopyridines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201016 |